The table below is a review of notable updates that occurred in January 2025 for investigational products in development.

We recently published a list of Jim Cramer Discusses These 11 Stocks & President Trump’s Sovereign Wealth Fund.

The pharma giant said it has agreed to acquire the U.S. privately held, clinical-stage biopharmaceutical company to boost its ...

The agreement hands Biogen as much as $250 million in exchange for milestone payments and sales royalties for litifilimab, ...

Fulcrum Therapeutics' promising treatment for Sickle Cell Disease and their strong financial position, despite setbacks.

Anavex Life Sciences Corp. expects feedback from the European Medicines Agency on blarcamesine for Alzheimer's Disease this ...

Eli Lilly expects to provide results from a study in people with obesity and osteoarthritis of the knee in 2025.

sNDA accepted for Priority Review Datopotamab deruxtecan (AstraZeneca and Daiichi Sankyo) TROP2-directed DXd antibody drug conjugate Treatment of adults with locally advanced or metastatic ...

Sales of an Alzheimer’s disease treatment were better than expected, but that and a quarterly beat wasn’t enough to offset ...

Astellas has invested heavily in novel technologies that are not necessarily the most successful or popular in the industry.

In obesity, Lilly removed a dual amylin calcitonin receptor agonist (DACRA) from its phase 1 pipeline. Lilly got into DACRAs by partnering with KeyBioscience in 2017. At one time, the Big Pharma was ...

If you're focused on delivering a high return on capital for your shareholders, you should consider M&A as an integral part ...